Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ARS-853 + BAY-293 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ARS-853 | KRAS G12C inhibitor 36 | ARS-853 selectively inhibits KRAS G12C, resulting in a decrease in activated KRAS G12C and potentially leading to reduced growth of KRAS G12C-expressing tumor cells (PMID: 26739882, PMID: 32101243). | ||
| BAY-293 | BAY293|BAY 293 | SOS1 Inhibitor 17 | BAY-293 inhibits the interaction between Sos1 and Kras, leading to reduced Ras activation and downstream Erk phosphorylation, and potentially leading to decreased tumor cell proliferation (PMID: 30683722). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|